Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 12/20 | 0.50 |
| ▸ | RXRB | P28702 | 3/20 | 0.49 |
| ▸ | RXRG | P48443 | 3/20 | 0.49 |
| ▸ | RARG | P13631 | 8/20 | 0.46 |
| ▸ | RARB | P10826 | 5/20 | 0.46 |
| ▸ | RARA | P10276 | 5/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6870757 | 0.93 | RXRA (0.48) | RXRARXRBRXRGRARGRARB | |
| SCHEMBL6876044 | 0.90 | RXRA (0.45) | RXRARXRBRXRGRARGRARB | |
| SCHEMBL6876535 | 0.89 | RXRA (0.49) | RXRARXRBRXRGRARGRARB | |
| SCHEMBL6870966 | 0.87 | RXRA (0.54) | RXRARXRBRXRGRARGRARB | |
| SCHEMBL6878500 | 0.85 | RXRA (0.46) | RXRARXRBRXRGRARGRARB | |
| SCHEMBL6879446 | 0.84 | RXRA (0.67) | RXRARXRBRXRGRARGRARB | |
| SCHEMBL6877473 | 0.84 | RXRA (0.43) | RXRARXRBRXRGRARGRARB | |
| SCHEMBL6876422 | 0.82 | RXRA (0.66) | RXRARXRBRXRGRARGRARB | |
| SCHEMBL6880784 | 0.81 | RXRA (0.52) | RXRARXRBRXRGRARGRARB | |
| SCHEMBL6878335 | 0.81 | RARG (0.44) | RXRARXRBRXRGRARGRARB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6825360-B1 | Bicyclic aromatic compounds | GALDERMA RESEARCH & DEVELOPMENT S.N.C. (FR) | 2004-11-30 | — | — | US | disclosed |
| US-20030135053-A1 | For use in human or veterinary conditions, that may be dermatological, rheumatic, respiratory, or cardiovascular and may be used in cosmetics | BERNARDON JEAN-MICHEL | 2003-07-17 | — | — | US | disclosed |
| US-20030060491-A1 | Bicyclic aromatic compounds | BERNARDON JEAN-MICHEL (FR) | 2003-03-27 | — | — | US | disclosed |
| US-6147255-A | TOPICAL AND SYSTEMIC TREATMENT OF DERMATOLOGICAL COMPLAINTS ASSOCIATED WITH KERATINIZATION DISORDER WHICH HAS EFFECT ON DIFFERENTIATION AND ON PROLIFERATION | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (FR) | 2000-11-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030060491-A1 | Bicyclic aromatic compounds | MITF, TYR, PAH | RXRA 196/4885RXRB 238/4885RXRG 211/4885 |
| US-20030135053-A1 | For use in human or veterinary conditions, that may be dermatological, rheumatic, respiratory, or cardiovascular and may be used in cosmetics | MITF, TYR, PAH | RXRA 55/4885RXRB 91/4885RXRG 87/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.